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www.elsevier.com/locate/jcfEditorialEradication of Pseudomonas aeruginosa by early antibiotic
treatment has been one of the major advances in the last decade
for subjects with CF [1]. This fantastic success has let many
people to forget that this pathogen is not the only one present
in CF airways. The study by Vanderhelst and colleagues [2]
puts the finger on another dangerous bacterium, methicillin-
resistant Staphylococcus aureus (MRSA) which rose in
prevalence in CF from 0.1% in 1995 to 22% in 2007. Using
registry data from 2002 to 2010, their retrospective case–
control study showed that the prevalence of MRSA in
chronically S. aureus infected patients, was 15.2% from
which 12.6% were chronically infected. Importantly, MRSA
caused a more rapid lung function decline compared with
controls.
Where do these bacteria come from? What are the risk
factors for MRSA acquisition? Vanderhelst and colleagues
concluded that acquisition of MRSA was associated with
hospitalization, the F508del genotype and the presence of
bronchiectasis. Unfortunately, a molecular characterization of
the MRSA strains was not anymore possible, allowing a
clarification whether these MRSA strains are clonal, hospital
or community acquired and positive the Panton–Valentine
leukocidin or other virulence factors. Larger prospective
longitudinal studies are needed to close this gap in our
understanding and support the notion of the authors that
MRSA is present in more severely ill patients. Until then, and
based on their and other data [3], Vanderhelst and colleagues
emphasize the importance of segregation, hygiene, surveillance1569-1993/$ -see front matter © 2011 Published by Elsevier B.V. on behalf of Eur
doi:10.1016/j.jcf.2011.11.011and early eradication therapy for the management of MRSA
in CF.
The article in this issue on chronic methicillin-resistant
Staphylococcus aureus (MRSA) colonization in patients with
cystic fibrosis is free to download at cysticfibrosisjournal.com.References
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